



AVI BioPharma - Investor and Analyst Breakfast Recording and Presentations

9/10/08

Transitioning an Antisense Pioneer into a Leading RNA-based Drug Discovery and Development Company

September 10, 2008

Dr. Leslie Hudson, President and CEO, AVI BioPharma

RNA-based drug discovery and development

[Audio \(MP3\)](#), [Slides \(PDF\)](#)

Professor Francesco Muntoni, Professor of Pediatric Neurology, Head of the Dubowitz Neuromuscular Centre, University College London Institute of Child Health, London, UK

Duchenne Muscular Dystrophy (DMD): The disease, its clinical management and future treatment

[Audio Part 1 \(MP3\)](#), [Audio Part 2 \(MP3\)](#), [Slides \(PDF\)](#)

Dr. Leslie Hudson

Clinical Trials of AVI-4658 and the commercial prospects for a DMD franchise

[Audio \(MP3\)](#), [Slides \(PDF\)](#)

Dr. Ryszard Kole, SVP of Discovery Research, AVI BioPharma

Directed alternative splicing mediated by novel oligomers with increased potency and bioavailability

[Audio \(MP3\)](#), [Slides \(PDF\)](#)

Benjamin D. Johnson, Engineering Manager, Global Therapeutics, a COOK Medical Company

Developing a breakthrough drug-eluting stent (DES) technology using the GTX platform and an improved application of antisense therapy: AVI-5126

[Audio \(MP3\)](#), [Slides \(PDF\)](#)

Dr. Patrick Iversen, SVP of Strategic Alliances, AVI BioPharma

Biodefense priorities for AVI and the enablement of HCV drug discovery

[Audio Part 1 \(MP3\)](#), [Audio Part 2 \(MP3\)](#), [Slides \(PDF\)](#)

J. David Boyle, SVP Finance and CFO, AVI BioPharma

Building an RNA-based drug discovery and development company

[Audio \(MP3\)](#), [Slides \(PDF\)](#)